LCTX-Short term long opportunity , AlphaOverBeta Price Alert
LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally.
The company has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Sector: Healthcare
Industry: Biotechnology
Market Cap(M$): 165
52 Week High: 1.67$
52 Week Low: 0.53$
Forward PE: -6.11
Analysts Recommendations
2015-12-22, Oppenheimer, Outperform
2016-02-19, Chardan Capital, Buy
2016-09-23, Ladenburg Thalmann, Buy
2019-03-18, Raymond James, Outperform
Technical Analysis:
Analyzing the stock from a technical perspective, we have these conclusions:
The stock is in an uptrend in the short-term and is expected to continue this trend for the next few days.
short-term momentum is positive and medium-term momentum looks positive based on technical momentum indicators for the perspective time periods.
Oversold/Overbought: the stock is overbought in the short term and is overbought in the medium term.
the recent trigger to buy/sell based on technical triggers is to buy.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally.
The company has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Sector: Healthcare
Industry: Biotechnology
Market Cap(M$): 165
52 Week High: 1.67$
52 Week Low: 0.53$
Forward PE: -6.11
Analysts Recommendations
2015-12-22, Oppenheimer, Outperform
2016-02-19, Chardan Capital, Buy
2016-09-23, Ladenburg Thalmann, Buy
2019-03-18, Raymond James, Outperform
Technical Analysis:
Analyzing the stock from a technical perspective, we have these conclusions:
The stock is in an uptrend in the short-term and is expected to continue this trend for the next few days.
short-term momentum is positive and medium-term momentum looks positive based on technical momentum indicators for the perspective time periods.
Oversold/Overbought: the stock is overbought in the short term and is overbought in the medium term.
the recent trigger to buy/sell based on technical triggers is to buy.
คำจำกัดสิทธิ์ความรับผิดชอบ
ข้อมูลและบทความไม่ได้มีวัตถุประสงค์เพื่อก่อให้เกิดกิจกรรมทางการเงิน, การลงทุน, การซื้อขาย, ข้อเสนอแนะ หรือคำแนะนำประเภทอื่น ๆ ที่ให้หรือรับรองโดย TradingView อ่านเพิ่มเติมที่ ข้อกำหนดการใช้งาน